{"denoms":[{"counts":[{"groupId":"BG000","value":"338"},{"groupId":"BG001","value":"338"},{"groupId":"BG002","value":"337"},{"groupId":"BG003","value":"1013"}],"units":"Participants"}],"groups":[{"description":"During chemotherapy (combination) stage:\n\nPatients received tremelimumab 75 mg + durvalumab 1500 mg combination therapy + SoC chemotherapy via IV infusion Q3W for 4 doses/cycles (Weeks 0, 3, 6 and 9).\n\nThe SoC chemotherapy was the Investigator's choice of one of the following regimens: abraxane + carboplatin (squamous and non-squamous patients), pemetrexed + cisplatin or carboplatin (non-squamous patients only), or gemcitabine + cisplatin or carboplatin (squamous patients only).\n\nPost-chemotherapy (maintenance) stage:\n\nPatients then continued to receive durvalumab monotherapy 1500 mg IV infusion Q4W from Week 12 until PD, unless there was unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met. Patients also received an additional dose of tremelimumab 75 mg (in combination with durvalumab) at Week 16 post-chemotherapy.\n\nNon-squamous patients who received pemetrexed + carboplatin/cisplatin during chemotherapy stage could receive pemetrexed maintenance therapy, given Q4W from Week 12 until PD, unless contraindicated per the Investigator.","id":"BG000","title":"T + D + SoC"},{"description":"During chemotherapy (combination) stage:\n\nPatients received durvalumab 1500 mg monotherapy + SoC chemotherapy via IV infusion Q3W for 4 doses/cycles (Weeks 0, 3, 6 and 9).\n\nThe SoC chemotherapy was the Investigator's choice of one of the following regimens: abraxane + carboplatin (squamous and non-squamous patients), pemetrexed + cisplatin or carboplatin (non-squamous patients only), or gemcitabine + cisplatin or carboplatin (squamous patients only).\n\nPost-chemotherapy (maintenance) stage:\n\nPatients then continued to receive durvalumab monotherapy 1500 mg IV infusion Q4W from Week 12 until PD, unless there was unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.\n\nNon-squamous patients who received pemetrexed + carboplatin/cisplatin during chemotherapy stage could receive pemetrexed maintenance therapy, given Q4W from Week 12 until PD, unless contraindicated per the Investigator.","id":"BG001","title":"D + SoC"},{"description":"During chemotherapy (combination) stage:\n\nPatients received SoC chemotherapy alone via IV infusion Q3W for 4 doses/cycles (Weeks 0, 3, 6 and 9). Patients could also receive SoC chemotherapy for an additional 2 cycles Q3W on Weeks 12 and 15 if clinically indicated and at the Investigator's discretion before the patient entered follow-up.\n\nThe SoC chemotherapy was the Investigator's choice of one of the following regimens: abraxane + carboplatin (squamous and non-squamous patients), pemetrexed + cisplatin or carboplatin (non-squamous patients only), or gemcitabine + cisplatin or carboplatin (squamous patients only).\n\nPost-chemotherapy (maintenance) stage:\n\nNon-squamous patients who received pemetrexed + carboplatin/cisplatin during chemotherapy stage could receive pemetrexed maintenance therapy, given Q3W or Q4W (dependent on Investigator decision and local standards) from Week 12 until PD, unless contraindicated per the Investigator.","id":"BG002","title":"SoC Alone"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.43","value":"62.6"},{"groupId":"BG001","spread":"9.10","value":"63.5"},{"groupId":"BG002","spread":"9.87","value":"63.1"},{"groupId":"BG003","spread":"9.47","value":"63.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"89"},{"groupId":"BG003","value":"243"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"269"},{"groupId":"BG001","value":"253"},{"groupId":"BG002","value":"248"},{"groupId":"BG003","value":"770"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"205"},{"groupId":"BG001","value":"182"},{"groupId":"BG002","value":"179"},{"groupId":"BG003","value":"566"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"20"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"123"},{"groupId":"BG002","value":"128"},{"groupId":"BG003","value":"350"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}],"title":"Native Hawaiian or other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"38"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"37"}],"title":"Other"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"55"},{"groupId":"BG003","value":"160"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"287"},{"groupId":"BG001","value":"284"},{"groupId":"BG002","value":"282"},{"groupId":"BG003","value":"853"}],"title":"Not Hispanic or Latino"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"86"}],"title":"≥18 to <50"},{"measurements":[{"groupId":"BG000","value":"162"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"146"},{"groupId":"BG003","value":"450"}],"title":"≥50 to <65"},{"measurements":[{"groupId":"BG000","value":"112"},{"groupId":"BG001","value":"130"},{"groupId":"BG002","value":"121"},{"groupId":"BG003","value":"363"}],"title":"≥65 to <75"},{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"114"}],"title":"≥75"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age Categorical","unitOfMeasure":"Participants"}],"populationDescription":"Global cohort: All patients in the full analysis set (FAS), which included all randomized patients, were included in the baseline analysis. Patients were included in the analysis in the treatment arm to which they were randomized, regardless of the treatment they received."}